Xuesong Huang, Lei Zheng, Mingkun Zhang*, Annie Xiaoyu An, Jing Zhao*, Xiang Gao*, Jean-Pierre Wery, Qian Shi, and Davy Xuesong Ouyang
*Nanjing Galaxy Biopharmaceutical Co. Ltd., Nanjing, China
OX40 is a co-stimulatory receptor of the TNF receptor superfamily, and is at the forefront of the “T cell co-stimulation” field. While not constitutively expressed on resting, naïve T cells, OX40 instead serves as a secondary co-stimulatory immune checkpoint molecule on activated effector and regulatory T cells.
OX40 agonistic antibodies are already being assessed in the clinic as both single agent and combination regimens. Preclinical evaluation of these agents is, however, hampered by a lack of reliable models to test human origin agents.
To meet this need, CrownBio has developed a humanized drug target knock-in GEMM, where the entire mouse OX40 coding region is replaced with the human counterpart, allowing assessment of OX40 human-specific mAb therapeutics.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2021-10-28
2021-10-28
landing_page
PDX/Databases